These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

35 related articles for article (PubMed ID: 28950390)

  • 1. Sphingosine kinase-2 Inhibitor ABC294640 Enhances Doxorubicin-Induced Apoptosis of NSCLC Cells via Altering Survivin Expression.
    Hasanifard L; Samadi N; Rashtchizadeh N; Dastmalchi S; Karimi P
    Drug Res (Stuttg); 2018 Jan; 68(1):45-53. PubMed ID: 28950390
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antitumor effect of the novel sphingosine kinase 2 inhibitor ABC294640 is enhanced by inhibition of autophagy and by sorafenib in human cholangiocarcinoma cells.
    Ding X; Chaiteerakij R; Moser CD; Shaleh H; Boakye J; Chen G; Ndzengue A; Li Y; Zhou Y; Huang S; Sinicrope FA; Zou X; Thomas MB; Smith CD; Roberts LR
    Oncotarget; 2016 Apr; 7(15):20080-92. PubMed ID: 26956050
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sphingosine kinase-2 silencing modulates sensitivity of HT-29 human colorectal cancer cells to paclitaxel-induced cell death through altering apoptosis-related proteins.
    Mu Y; Wang J; Li G
    Chem Biol Drug Des; 2023 Aug; 102(2):255-261. PubMed ID: 36929215
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of sphingosine kinase-2 suppresses inflammation and attenuates graft injury after liver transplantation in rats.
    Liu Q; Rehman H; Shi Y; Krishnasamy Y; Lemasters JJ; Smith CD; Zhong Z
    PLoS One; 2012; 7(7):e41834. PubMed ID: 22848628
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery and biological evaluation of biaryl acetamide derivatives as selective and in vivo active sphingosine kinase-2 inhibitors.
    Li Y; Li G; Wang Y; Li L; Song Y; Cao F; Yang K
    Eur J Med Chem; 2024 Sep; 275():116577. PubMed ID: 38875809
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of sphingosine kinase-2 in a murine model of lupus nephritis.
    Snider AJ; Ruiz P; Obeid LM; Oates JC
    PLoS One; 2013; 8(1):e53521. PubMed ID: 23301082
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting sphingosine kinase 2 suppresses cell growth and synergizes with BCL2/BCL-XL inhibitors through NOXA-mediated MCL1 degradation in cholangiocarcinoma.
    Ding X; Zhang Y; Huang T; Xu G; Peng C; Chen G; Kong B; Friess H; Shen S; Lv Y; Roberts LR; Wang L; Zou X
    Am J Cancer Res; 2019; 9(3):546-561. PubMed ID: 30949409
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Survivin reduces activation-induced T cell death in G1 phase.
    Shon HK; Cho KJ; Chung AS
    Mol Cells; 2003 Oct; 16(2):147-53. PubMed ID: 14651254
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pioneering 4,11-Dioxo-4,11-dihydro-1
    Yuan J; Liu Z; Dong Y; Gao F; Xia X; Wang P; Luo Y; Zhang Z; Yan D; Zhang W
    J Med Chem; 2023 Dec; 66(24):16843-16868. PubMed ID: 38079530
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative Studies of Resveratrol, Oxyresveratrol and Dihydrooxyresveratrol on Doxorubicin-Treated Lung Cancer Cells.
    Yahayo W; Pongkittiphan V; Supabphol R; Saiyudthong S
    Asian Pac J Cancer Prev; 2024 Mar; 25(3):939-949. PubMed ID: 38546076
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synergistic anticancer effects of SMYD2 inhibitor BAY-598 and doxorubicin in non-small cell lung cancer.
    Meng J; Yang W; Li C; Li F
    Heliyon; 2024 Jun; 10(11):e32015. PubMed ID: 38947456
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Sphingolipid-Modulating Drug Opaganib Protects against Radiation-Induced Lung Inflammation and Fibrosis: Potential Uses as a Medical Countermeasure and in Cancer Radiotherapy.
    Maines LW; Keller SN; Smith RA; Green CL; Smith CD
    Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38396999
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined Antitumor Effect of the Serine Protease Urokinase Inhibitor Upamostat and the Sphingosine Kinase 2 Inhibitor Opaganib on Cholangiocarcinoma Patient-Derived Xenografts.
    Asumda FZ; Campbell NA; Hassan MA; Fathi R; Vasquez Rico DF; Kiem M; Vang EV; Kim YH; Luo X; O'Brien DR; Buhrow SA; Reid JM; Moore MJ; Ben-Yair VK; Levitt ML; Leiting JL; Abdelrahman AM; Zhu X; Lucien F; Truty MJ; Roberts LR
    Cancers (Basel); 2024 Mar; 16(5):. PubMed ID: 38473407
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of doxorubicin and apigenin on chronic myeloid leukemia cells (K562)
    Noorian M; Chamani E; Salmani F; Rezaei Z; Khorsandi K
    Nat Prod Res; 2023; 37(19):3335-3343. PubMed ID: 35503006
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Developing new ceramide analogs against non-small cell lung cancer (NSCLC).
    Dai L; Goyal N; Liu J; Foroozesh M; Qin Z
    Am J Cancer Res; 2024; 14(1):86-96. PubMed ID: 38323290
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recent Progress in the Development of Opaganib for the Treatment of Covid-19.
    Smith CD; Maines LW; Keller SN; Katz Ben-Yair V; Fathi R; Plasse TF; Levitt ML
    Drug Des Devel Ther; 2022; 16():2199-2211. PubMed ID: 35855741
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis, Biological Activity, and Molecular Modelling Studies of Naphthoquinone Derivatives as Promising Anticancer Candidates Targeting COX-2.
    Kavaliauskas P; Opazo FS; Acevedo W; Petraitiene R; Grybaitė B; Anusevičius K; Mickevičius V; Belyakov S; Petraitis V
    Pharmaceuticals (Basel); 2022 Apr; 15(5):. PubMed ID: 35631366
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting Sphingolipids for Cancer Therapy.
    Companioni O; Mir C; Garcia-Mayea Y; LLeonart ME
    Front Oncol; 2021; 11():745092. PubMed ID: 34737957
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of sphingosine kinase 2 attenuates hypertrophic scar formation via upregulation of Smad7 in human hypertrophic scar fibroblasts.
    Zeng J; Jiang B; Xiao X; Zhang R
    Mol Med Rep; 2020 Sep; 22(3):2573-2582. PubMed ID: 32705254
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting Sphingosine Kinases for the Treatment of Cancer.
    Lewis CS; Voelkel-Johnson C; Smith CD
    Adv Cancer Res; 2018; 140():295-325. PubMed ID: 30060814
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 2.